{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-028869","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2023-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.450890+00:00","generated_at":"2026-06-19T20:41:00.149892+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Erasca extends cash runway to H2 2025, accelerates naporafenib and ERAS-601 readouts","bullets":["Cash runway extended from H1 2025 to H2 2025; resources focused on naporafenib and ERAS-007/601 sub-studies.","SEACRAFT-1 (naporafenib in RAS Q61X solid tumors) data readout accelerated to Q2-Q4 2024 from H2 2024-H1 2025.","FLAGSHP-1 (ERAS-601 in HPV-neg HNSCC) data readout accelerated to H1 2024 from calendar year 2024.","HERKULES-3 (ERAS-007/601 in BRAFm CRC) data readout affirmed for H2 2023-H1 2024.","Other milestones: SEACRAFT-2 Ph3 FPD in NRASm melanoma H1 2024, THUNDERBBOLT-1 Ph1 data in rGBM H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-028869","json":"https://secwatch.observer/filing/0001193125-23-028869.json","markdown":"https://secwatch.observer/filing/0001193125-23-028869.md","text":"https://secwatch.observer/filing/0001193125-23-028869.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000119312523028869/0001193125-23-028869-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000119312523028869/d382775d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T20:41:00.149892+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}